However, approximately 30–50% of patients (depending on dose) after receiving IFN-α therapy develop IFN-α-induced depression, with symptoms consistent with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for major depression [2–4]. Here, IFNA1 is linked to depressive symptom measurement.